A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors' previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine infusion in individuals with PTSD showed significant and rapid PTSD symptom reduction 24 hours postinfusion. The present study is the first randomized controlled trial to test the efficacy and safety of repeated intravenous ketamine infusions for the treatment of chronic PTSD. METHODS: Individuals with chronic PTSD (N=30) were randomly assigned (1:1) to receive six infusions of ketamine (0.5 mg/kg) or midazolam (0.045 mg/kg) (psychoactive placebo control) over 2 consecutive weeks. Clinician-rated and self-report assessments were administered 24 hours after the first infusion and at weekly visits. The primary outcome measure was change in PTSD symptom severity, as assessed with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), from baseline to 2 weeks (after completion of all infusions). Secondary outcome measures included the Impact of Event Scale-Revised, the Montgomery-Åsberg Depression Rating Scale (MADRS), and side effect measures. RESULTS: The ketamine group showed a significantly greater improvement in CAPS-5 and MADRS total scores than the midazolam group from baseline to week 2. At week 2, the mean CAPS-5 total score was 11.88 points (SE=3.96) lower in the ketamine group than in the midazolam group (d=1.13, 95% CI=0.36, 1.91). Sixty-seven percent of participants in the ketamine group were treatment responders, compared with 20% in the midazolam group. Among ketamine responders, the median time to loss of response was 27.5 days following the 2-week course of infusions. Ketamine infusions were well tolerated overall, without serious adverse events. CONCLUSIONS: This randomized controlled trial provides the first evidence of efficacy of repeated ketamine infusions in reducing symptom severity in individuals with chronic PTSD. Further studies are warranted to understand ketamine's full potential as a treatment for chronic PTSD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another study of repeat-dose ketamine (six infusions over two weeks, n = 30) found a response rate of 67% [102]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [102]
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 2×
“…were assessed before infusion and at 40 and 120 minutes after start of infusion with the Clinician-Administered Dissociative States Scale (28), the 4-item positive symptom subscale of the Brief Psychiatric Rating Scale (29), and the fi rst item (elevated mood) of the Young Mania Rating Scale (30).”
MethodPosner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“…a rapid increase in glutamate release, triggering several downstream signaling pathways (including brain-derived neurotrophic factor [BDNF] and mammalian target of rapamycin complex 1 [mTORC1]), resulting in increased synaptogenesis and synaptic spine maturation in key brain regions (33, 34).”
BackgroundAssessing psychological trauma and PTSD
(1997) · Choice Reviews Online · doi:10.5860/choice.34-5966 · Cited by 2,330
Weathers, F. W., Bovin, M. J., Lee, D. J., Sloan, D. M., Schnurr, P. P., Kaloupek, D. G., Keane, T. M., & Marx, B. P. (2018) · Psychological Assessment · doi:10.1037/pas0000486 · Cited by 1,799 · cited 15×
“The study involved three phases: 1) screening, during which participants were assessed for eligibility and any required medication tapering took place; 2) a 2-week treatment phase, during which participants received six in-fusionsofstudydrugapproximatelythreetimesperweekand were assessed on each infusion day, as well…”
MethodInfluentialTrauma and PTSD in the WHO World Mental Health Surveys
Kessler, R. C., Aguilar-Gaxiola, S., Alonso, J., Benjet, C., Bromet, E. J., Cardoso, G., Degenhardt, L., de Girolamo, G., Dinolova, R. V., Ferry, F., et al. (2017) · European Journal of Psychotraumatology · doi:10.1080/20008198.2017.1353383 · Cited by 1,661 · cited 1×
“Rates vary by trauma type, severity, and cumulative trauma exposure, with the highest PTSD burden among survivors of interpersonal violence (2).”
BackgroundKetamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260 · cited 1×
“…to develop novel pharmacologic interventions for chronic PTSD. Ketamine, fi rstapprovedbytheFDAasananestheticagent in 1970 (11), is a noncompetitive glutamate N -methyl- D -as- partate (NMDA) receptor antagonist, with lower af fi nity for serotonin, dopamine, opioid, and other receptors (12).”
Background
Research works printed but not linked: 2
- Golier JA, 2012, Depress Res Treat, 2012, 393251
- First MB, 2015, Structured Clinical Interview for DSM-5—Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV)
Cited by
Items 201–246 of 246
Chapter 51. Treatment of Posttraumatic Stress Disorder
Nemeroff, C. B., Rosen, V., & Ortiz, N. F. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as51
Medications for Anxiety Disorders
Narita, Z. C., Fujimoto, M., Winter, E., Nestadt, P. S., & Sawa, A. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_136
Johnson, D. E., Rodrigues, N. B., Weisz, S., Chisamore, N., Kaczmarek, E. S., Chen-Li, D. C. J., Doyle, Z., Richardson, J. D., Mansur, R. B., McIntyre, R. S., et al. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.11.008 · Cited by 6
Biological Mechanisms of Stress Resilience: Human and Animal Studies
Seeley, S. H., Boukezzi, S. C., DePierro, J. M., Charney, D. S., & Feder, A. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197640654.003.0041 · Cited by 2
Self-citationKetamine: New Uses for an Old Drug?
Jones, N., & Frost, E. A. M. (2025) · Topics in Pain Management · doi:10.1097/01.tpm.0001108044.62000.1d
Effectiveness of Pharmacological Treatment for PTSD: A Systematic Review
Vyas, D., Tripathi, S., & Goel, D. (2025) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-7432-0.ch022
Ketamine and Hydroxynorketamine: The Complex Balancing Act Within Fear Neural Ensembles
Kim, J. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.02.899
Treatment of Depressive Episodes
Herrero, A., & Grande, I. (2025) · Springer eBooks · doi:10.1007/978-3-031-85519-1_22
Emerging Use of Low-Dose Ketamine for Pain Management Beyond the ICU
Oza, E., Rateshwar, Y., Santhosh, A., & Dave, V. (2025) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360288.2025.2532657
Ketamine/esketamine for treatment-resistant depression
Nikayin, S., & Sanacora, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00013-x · Cited by 6
Hughes, B., Mirza, S., Ponamala, M., Sagaser, J., Paredes, R., Hematillake, N., Tailor, C., Khan, R., & Pemminati, S. (2025) · Cureus · doi:10.7759/cureus.90425 · Cited by 2
Therapeutic Potential of Psychedelics: Mechanisms, Applications, and Challenges
Castaño-Perez, G., & Castaño-Ocampo, S. I. (2025) · Pharmaceutical science. · doi:10.5772/intechopen.1011560
Ketamine’s Multifaceted Neuropharmacological and Neurobiological Actions
Kohtala, S., & Annala, I. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_2
Byshek, M. Y., Piliponova, V. V., Shypitsyna, O. V., & Tkachenko, T. V. (2025) · Reports of Vinnytsia National Medical University · doi:10.31393/reports-vnmedical-2025-29(3)-05
Gregoire, N., Klukas, E., Kaseweter, K., Louw, W. F., & Davies, P. G. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06948-y
“Posttraumatic Stress Disorder (PTSD) itself is distinct from trauma exposure and requires experiencing a criterion A traumatic event accompanied by symptom clusters of re-experiencing, avoidance, negative alterations in cognition and mood, and hyperarousal (American Psychiatric Association, 2013).”
InfluentialCanada, A. (2025) · Nursing Clinics of North America · doi:10.1016/j.cnur.2025.09.004
Maeder, S., Fahim, C., & Martin-Söelch, C. (2025) · Cortica · doi:10.26034/cortica.2025.8925
“It has demonstrated rapid antidepressant effects and promising though mixed results for PTSD (Feder, 2021; Sicignano, 2024).”
InfluentialKetamine as a prophylactic agent against post-traumatic stress disorder
Peavey, J. (2023) · Journal of High School Science · doi:10.64336/001c.87422
Wongpaiboon, M., Shelton, J. L., Rendon, E. D., & Vail, M. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00373-w · Cited by 2
“Single-dose RCTs [ 42, 43, 45 , 46 ] demonstrated marked improvement in as soon as four to 24 h in some studies with mean PCL-5 decreases of 25 to 50 points and CAPS reductions of 20 to 40 points [ 44 ].”
The Scarred Circuitry of Fear: A Computational–Clinical Synthesis of PTSD NeurobiologyPreprint
filho, R. M. P. A. (2026) · Qeios · doi:10.32388/76fbo7
Byshek, M. Y., Berezovskyi, A. M., Piliponova, V. V., Сорокоумов, В. П., Fedorchenko, O. V., Bondаr, S. А., & Terekhovskyi, A. I. (2026) · World of Medicine and Biology · doi:10.26724/2079-8334-2025-4-94-216-221
Cutting, T., & Hartman, R. E. (2026) · Medicine Advances · doi:10.1002/med4.70051
“Follow‐up studies with multiple infusions also demonstrated significant symptom reduction, which lasted a median of 27.5 days for PTSD and 20 days for depression, indicating dose frequency dependence [61, 62].”
InfluentialMALEKZADEH, M. H., Afzali, S. M., & Dasdar, S. (2026) · Trials · doi:10.1186/s13063-026-09499-5
“Various treatments exist for PTSD, including pharmacotherapy [18], light therapy [19], yoga [20], and cognitive-behavioral therapy (CBT) [21].”
The Scarred Circuitry of Fear: A Computational–Clinical Synthesis of PTSD NeurobiologyPreprint
filho, R. M. P. A. (2026) · Qeios · doi:10.32388/76fbo7.2
filho, R. M. P. A. (2026) · Qeios · doi:10.32388/76fbo7.3
Ketamine in clinical psychiatry and addictology - a narrative review
Vašíček, O., & Páleníček, T. (2026) · Psychiatrie pro praxi · doi:10.36290/psy.2026.004
Cheung, N. (2026) · Cureus · doi:10.7759/cureus.108751
“This case differs from ketamine PTSD trials, which generally involve supervised intravenous administration and shorter acute-response windows [9,10].”
Kamene, K. (2026) · Premier Journal of Neuroscience · doi:10.70389/pjn.100014
Raffone, F., Cattaneo, C. I., Pessina, E., Martini, A., & Martiadis, V. (2026) · Behavioral Sciences · doi:10.3390/bs16050771 · Cited by 1
“RCT = randomised controlled trial; TRD = treatment-resistant depression; PTSD = post-traumatic stress disorder; IV = intravenous; WET = written exposure therapy; EMDR = eye movement desensitization and reprocessing.”
InfluentialЧорномидз, А. В. (2026) · Здобутки клінічної і експериментальної медицини · doi:10.11603/1811-2471.2026.v.i1.16129
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551944.bm01
Curran, C., Hernandez, E. J., Hudnall, J., Sra, J., & Davis, M. E. (2026) · Pain Management · doi:10.1080/17581869.2026.2682470
Parks, A. C., Woodward, A. L., Vlisides‐Henry, R. D., Arden, K., Vando, L., Swain, J., & Lamichhane, B. (2026) · Journal of Medical Internet Research · doi:10.2196/92647 · Cited by 1
“Ketamine, a noncompetitive N-methyl-D-aspartate receptor antagonist, has emerged as a viable treatment option for depressive and anxious symptoms, including trauma-related symptoms [30-32].”
NMDA receptor–dependent structural plasticity links early life stress to persistent aggression
Jacobs, J. T., & Nordman, J. C. (2026) · Neurobiology of Stress · doi:10.1016/j.ynstr.2026.100831
“Follow-up studies using repeated-dose regimens reported more sustained therapeutic effects, with symptom improvements comparable to established trauma-focused psychotherapies (Duek et al., 2023; Feder et al., 2021).”
Glue, P., & Beaglehole, B. (2026) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70225
Averill, L. A., & Neitzke‐Spruill, L. (2026) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20260006
Cahill, J. D., & Gallagher, K. (2026) · Cambridge University Press eBooks · doi:10.1017/9781108689229.010
Advancing Social Justice in Psychiatric Prescribing
DeSouza, F., & Harding, L. (2026) · Cambridge University Press eBooks · doi:10.1017/9781108689229.020
Scientific Basis of Ketamine in Immunomodulation
Luetkemeier, M. K., Wentling, J. G., Ahmadzadeh, S., Shekoohi, S., & Kaye, A. D. (2026) · Springer eBooks · doi:10.1007/978-3-032-25214-2_4
Management of Posttraumatic Stress Disorder with Anesthetic Techniques
Dhesi, M., & Cheng, J. (2026) · Springer eBooks · doi:10.1007/978-3-032-25214-2_17
Berner, J. E. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1910337
“…in trials for mood disorder (1), treatment-resistant depression (2), pain (3), opioid dependence (4), and post-traumatic stress disorder (PTSD) (5); case reports describing response in psychosis also exist, challenging the academic n-methyl-d-aspartate (NMDA) receptor hypofunction model of…”
Zhao, X., Yu, Y., Liu, X., Zang, Z., & Wang, Q. (2026) · Research Square · doi:10.21203/rs.3.rs-10668891/v1
Ketamine-Assisted Intensive Short-Term Dynamic Psychotherapy
Kalpin, A. (2026) · Psychoanalytic Inquiry · doi:10.1080/07351690.2026.2721956
Research Progress on Post-Traumatic Stress Disorder in Emergency Trauma Patients
李, 杨. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1693113
Hu, B., Ortiz-Cruz, A., Sachidanandan, R. F., Ramiro, C., & Bourgeois, J. A. (2026) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2026.09.005
Ivasyutyn, M., & Bhakta, S. (2026) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70425
“27,28 Military and veteran populations: Descriptive findings 32 Veterans constituted a significant proportion of the study populations reviewed and were among the most frequently examined subgroups receiving ketamine interventions for PTSD.”
Influential
Metadata
- Authors
- Feder, A., Costi, S., Rutter, S. B., Collins, A. B., Govindarajulu, U., Jha, M. K., Horn, S. R., Kautz, M., Corniquel, M., Collins, K. A., Bevilacqua, L., Glasgow, A. M., Brallier, J., Pietrzak, R. H., Murrough, J. W., & Charney, D. S.
- Affiliations
- Nathan Kline Institute for Psychiatric Research (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2021-02-01
- Volume
- 178
- Issue
- 2
- Pages
- 193-202
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W3120445729
- Cited by
- 246
- References
- 37
- Citations by year
- 2026: 43 · 2025: 43 · 2024: 41 · 2023: 50 · 2022: 47 · 2021: 22
- FWCI
- 27.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- post-traumatic stress disorder, chronic PTSD, ketamine, treatment response durability, depression, adverse effects, pharmacotherapy
- MeSH terms
- Adolescent, Adult, Aged, Antidepressive Agents, Chronic Disease, Depression, Double-Blind Method, Female, Humans, Ketamine, Male, Middle Aged, Stress Disorders, Post-Traumatic, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.